MEDICLINIC INTERNATIONAL PLC

(MDC)
  Report
Delayed London Stock Exchange  -  11:35 2022-06-30 am EDT
457.80 GBX   +0.04%
06/23TRANSCRIPT : Mediclinic International plc - Special Call
CI
06/23DIMENSIONAL FUND ADVISORS LTD. : Form 8.3 - MEDICLINIC INTERNATIONAL PLC - Ordinary Shares
AQ
06/22MEDICLINIC INTERNATIONAL PLC : Good timing to anticipate a continuation of the trend
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mediclinic International Plc : Good timing to anticipate a continuation of the trend

06/22/2022 | 04:19am EDT
long trade
Live
Entry price : 436.2GBX | Target : 600GBX | Stop-loss : 370GBX | Potential : 37.55%
The underlying tendency is to the upside for shares in Mediclinic International plc and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Investors have an opportunity to buy the stock and target the GBX 600.
Mediclinic International Plc : Mediclinic International Plc : Good timing to anticipate a continuation of the trend
Summary
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company appears to be poorly valued given its net asset value.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company is not the most generous with respect to shareholders' compensation.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Hospitals, Clinics & Primary Care Services
1st jan.Capitalization (M$)Investor Rating
MEDICLINIC INTERNATIONAL PL..42.88%4 101
AIER EYE HOSPITAL GROUP CO...5.89%33 578
DR. SULAIMAN AL HABIB MEDIC..20.07%18 377
FRESENIUS SE & CO. KGAA-18.36%17 040
IHH HEALTHCARE BERHAD-12.13%13 001
RAMSAY HEALTH CARE LIMITED2.43%11 469
BANGKOK DUSIT MEDICAL SERVI..8.70%11 281
APOLLO HOSPITALS ENTERPRISE..-25.94%6 760
MOUWASAT MEDICAL SERVICES C..22.55%5 757
PREMIER, INC.-13.34%4 284
THE ENSIGN GROUP, INC.-12.49%4 152
More Results

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2022 3 206 M 3 896 M 3 896 M
Net income 2022 171 M 208 M 208 M
Net Debt 2022 1 958 M 2 380 M 2 380 M
P/E ratio 2022 21,2x
Yield 2022 0,56%
Capitalization 3 375 M 4 101 M 4 101 M
EV / Sales 2022 1,66x
EV / Sales 2023 1,46x
Nbr of Employees 33 683
Free-Float 55,3%
Upcoming event on MEDICLINIC INTERNATIONAL PLC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 457,80 GBX
Average target price 430,75 GBX
Spread / Average Target -5,91%
EPS Revisions
Managers and Directors
C. A. Ronnie van der Merwe Chief Executive Officer & Executive Director
Petrus Jurgens Myburgh Chief Financial Officer & Executive Director
Inga Kristine Beale Non Executive Chairman
Dirk Le Roux Chief Information Officer
Rene Toua Chief Clinical Officer